Trinity gains bioMerieux blood coagulation testing line
This article was originally published in The Gray Sheet
Executive Summary
Automated instruments and reagent menu for blood clotting parameter analysis composing bioMerieux's hemostasis product line are acquired by diagnostics firm Trinity Biotech May 25. Trinity will pay up to $51.9 mil., including $40 mil. at closing, with deferred payments of up to $11.9 mil. over two years. Combining the bioMerieux line with Trinity's existing coagulation testing products will add $40 mil. to Trinity's revenue next year and boost its share of the $600 mil. worldwide coagulation testing market from its current 5% level to an estimated 13%, the firm says. The market is growing at about 5% annually. The deal is in line with bioMerieux' focus on infectious diseases, cancer and cardiovascular diseases...
You may also be interested in...
BioMérieux Moves Forward With HPV, Sepsis Diagnostic Agreements
BioMérieux announced two deals last week as part of its five-year strategic plan focusing on infectious diseases and personalized diagnostics
US Q1 Consumer Health Earnings Preview: Label This One Historic And Challenging But Promising
US OTC drug and supplement firms’ reports of results for the first three months of 2024 began on April 19 with P&G. JP Morgan analysts say while “some retailers in the US in particular” are reducing consumer health inventories, for the overall sector they expect “a healthier balance of positive volume and lower pricing contribution.”
Keeping Track: Cancer Approvals From Lumisight Imaging To Adjuvant Alecensa
The US FDA’s approval of Lumicell’s optical imaging agent Lumisight makes a dozen novel approvals in 2024 for the Center for Drug Evaluation and Research.